bezafibrate has been researched along with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bordet, R; Destée, A; Gelé, P; Kreisler, A; Lhermitte, M; Wiart, JF | 1 |
| Bordet, R; Destée, A; Duhamel, A; Kreisler, A; Vanbesien-Mailliot, C | 1 |
2 other study(ies) available for bezafibrate and 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine
| Article | Year |
|---|---|
Lipid-lowering drugs in the MPTP mouse model of Parkinson's disease: fenofibrate has a neuroprotective effect, whereas bezafibrate and HMG-CoA reductase inhibitors do not.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Acyl Coenzyme A; Analysis of Variance; Animals; Bezafibrate; Cell Death; Disease Models, Animal; Drug Interactions; Fenofibrate; Hypolipidemic Agents; Male; Mice; Mice, Inbred C57BL; Monoamine Oxidase; MPTP Poisoning; PPAR alpha; Substantia Nigra | 2007 |
Differing short-term neuroprotective effects of the fibrates fenofibrate and bezafibrate in MPTP and 6-OHDA experimental models of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antiparkinson Agents; Apomorphine; Bezafibrate; Cell Count; Disease Models, Animal; Drug Interactions; Exploratory Behavior; Fenofibrate; Male; Mice; Mice, Inbred C57BL; Neuroprotective Agents; Oxidopamine; Parkinsonian Disorders; Statistics, Nonparametric; Substantia Nigra; Time Factors; Tyrosine 3-Monooxygenase; Ventral Tegmental Area | 2010 |